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expenses and turnaround. Further-
more, such mechanical procedures face 
species-specific difficulties regarding 
practicality. For example, the bovine and 
porcine zygotes appear opaque due to 
lipid droplets, making the pronucleus 
not readily discernable for microinjec-
tion. Previously, we and others devel-
oped a simple and efficient method for 
gene delivery to mouse preimplantation 
embryos of various developmental stages 
using recombinant adeno-associated virus 
(rAAV).[2] This technique allowed us to 
conveniently deliver the Cre recombinase 
or CRISPR components to mouse zygotes 
by incubating with rAAV expressing the related genes, which 
enabled highly efficient genome manipulation and generation 
of genetically modified mice.[2] We reasoned that rAAV may 
achieve gene transfer to zygotes of a broad range of mamma-
lian species widely used in biomedical research. In particular, 
when this technique is coupled with CRISPR delivery for 
genome editing, it represents an appealing alternative tech-
nique for animal modeling that overcomes several difficulties 
associated with microinjection, and can be potentially appli-
cable to various species commonly used as preclinical animal 
models.
In this study, we aim to demonstrate the feasibility of using 
rAAV for gene delivery to nonhuman primate (NHP) zygotes 
and genome editing. We chose cynomolgus monkey because 
it is a preferred NHP model in neuroscience research due to 
its similarities to humans in brain anatomy and function. We 
obtained zygotes by intracytoplasmic sperm injection (ICSI), 
and first screened rAAV of various serotypes expressing the 
enhanced green fluorescent protein (EGFP) for high trans-
duction capability (Figure S1a, Supporting Information). We 
adopted the established rAAV treatment protocol for mouse 
embryos, and selected the AAV serotypes that perform well in 
mouse embryos, including AAV6, AAV6.2, AAV7, AAVrh.39, 
and AAVrh.43.[2] NHP zygotes were incubated with 6 × 109 
genome copies (GC) of each rAAV for 5 h, rinsed, cultured 
for seven days ex vivo, and examined for EGFP fluorescence. 
Consistent with our previous mouse studies, all serotype vec-
tors transduced NHP embryos, and rAAV6 performed slightly 
better than the others (Figure S1b,c, Supporting Information). 
However, in contrast to mouse embryos that can tolerate the 
same rAAV treatment regimen,[2] NHP embryo development 
was severely compromised, resulting in most embryos stalling 
before the 8-cell stage and no embryos progressing to blastocyst 
Delivery of genome editing tools to mammalian zygotes has revolutionized 
animal modeling. However, the mechanical delivery method to introduce 
genes and proteins to zygotes remains a challenge for some animal species 
that are important in biomedical research. Here, an approach to achieve gene 
delivery and genome editing in nonhuman primate embryos is presented 
by infecting zygotes with recombinant adeno-associated viruses (rAAVs). 
Together with previous reports from the authors of this paper and others, this 
approach is potentially applicable to a broad range of mammals. In addition 
to genome editing and animal modeling, this rAAV-based method can 
facilitate gene function studies in early-stage embryos.
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Delivering CRISPR reagents to mammalian zygotes for gene 
editing has greatly expedited the generation of genetically 
modified animals such as cynomolgus monkeys.[1] However, 
the delivery of nucleic acids or proteins to preimplantation 
embryos mostly relies on laborious and time-consuming 
procedures including microinjection as well as specialized 
equipment and techniques that collectively incur substantial 
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(Figure S1c, Supporting Information). We next used a tenfold 
lower dose of rAAV6 that was also highly effective in trans-
ducing mouse embryos,[2] and tested various incubation dura-
tions ranging from 1 to 4 h (Figure S2a, Supporting Informa-
tion). Approximately 60% of embryos developed into blastocyst, 
comparable to our typical yield of blastocysts when embryos 
were cultured under the same condition without rAAV. The 
4 h incubation resulted in the most robust EGFP expression 
(Figure S2b,c, Supporting Information), although the EGFP 
signal was markedly weaker than the 6 × 109 GC infection 
(Figure S1b, Supporting Information). Together, this initial set 
of experiments demonstrated the capability of rAAV to trans-
duce NHP preimplantation embryos, and established an effec-
tive infection protocol.
To test whether rAAV infection of NHP zygotes can 
deliver CRISPR to realize genome editing, we chose to target 
the ASPA gene, mutations of which cause a fatal pediatric 
leukodystrophy called Canavan disease.[3] We designed three 
sgRNAs targeting a coding region in cynomolgus monkey 
ASPA exon 2 that is downstream of the start codon (sgASPA) 
(Figure 1a). The sgASPA targeting sequences were purpose-
fully chosen to be conserved between cynomolgus monkey 
Adv. Sci. 2019, 6, 1900440
Figure 1. AAV vectors transduced preimplantation NHP embryos and achieved genome editing. a) The cynomolgus monkey ASPA gene locus. The 
sequences encoding the start and stop codons are indicated by the green and red bars, respectively. Three sgRNAs are designed to target a region 
downstream of the start codon within exon 2 (blue). Arrows denote PCR primer binding sites to generate amplicons for analyzing editing efficiency. 
Not drawn to scale. b) Schematics showing the constructs expressing SpCas9 and sgRNA, respectively. c) Workflow including intracytoplasmic sperm 
injection (ICSI), embryo infection, ex vivo examination, and embryo transfer. d) Microscopic images of NHP embryos infected with AAV6 vectors at 
two doses. Green arrowheads indicate transduced embryos, and white arrowheads indicate nontransduced embryos. e) ASPA gene editing efficiency 
of individual embryos as determined by SMRT sequencing. Horizontal bars indicate the average values. f) T7EI assay of DNA from various tissues of 
six subjects derived from rAAV-infected embryos. PL: placenta (fetus side). UC: umbilical cord. BL: blood. CA: cardiac muscle. LI: liver. LU: lung. TE: 
testis. SK: skin. DNA from a naïve animal was used as control (ctrl).
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and African green monkey, so that the sgRNA targeting effi-
ciency can be conveniently evaluated in the COS-7 cell line that 
is derived from the latter species. Cotransfection of a pair of 
plasmids expressing SpCas9 and a single sgASPA (Figure 1b) 
in COS-7 cells resulted in insertion/deletion (indel) mutations 
in the ASPA gene, and sgASPA2 yielded the highest frequency 
of indel mutations as quantified by TOPO cloning of the 
targeted amplicons and Sanger sequencing of individual clones 
(Figure S3, Supporting Information). Therefore, the SpCas9 
and sgASPA2 constructs were separately packaged into AAV6 
for coinfecting zygotes at 1:1 ratio (Figure 1c).
Consistent with our initial experiments (Figures S1 and S2, 
Supporting Information), the high dose of 6 × 109 GC compro-
mised embryo development, whereas 6 × 108 GC was tolerated 
(Figure S4, Supporting Information), and transduction was 
largely dose-dependent as gauged by the EGFP fluorescence 
expressed from scAAV6.sgASPA (Figure 1d). A subset of 
embryos were individually harvested and analyzed for ASPA 
gene editing by single-molecule real-time (SMRT) sequencing. 
Two out of three embryos infected by the high-dose rAAVs were 
found to be completely edited, while the embryos infected by 
the low-dose rAAVs exhibited more variable editing efficiency 
ranging from 11% to 76% with an average of 31% (Figure 1e). 
Therefore, rAAV6 vectors can deliver CRISPR to NHP preim-
plantation embryos to afford targeted genome editing.
We further attempted to create cynomolgus monkeys with 
ASPA mutations, aiming to generate a NHP model of Canavan 
disease to further study the disease pathomechanisms and 
evaluate gene therapy.[4–6] To this end, we infected another 
batch of zygotes with rAAV6.SpCas9 and scAAV6.sgASPA2 
at 6 × 108 GC total, and transferred the normally cleaved 
embryos to surrogate females. Three weeks later, ultrasonog-
raphy revealed that five pregnancies were established carrying 
a total of nine fetuses. However, most fetuses underwent 
spontaneous abortion prior to full term. We obtained two live 
births and recovered four aborted fetuses at various develop-
mental stages (Table S1, Supporting Information). Tissues 
from these individuals were collected and subjected to DNA 
analysis. ASPA gene editing was not detected in the live births 
(#1–1 and #2–1) and one fetus aborted at 4 months likely due 
to the sick recipient (#3–1), whereas three fetuses aborted at 
1–2 months (#4–1, #4–2, and #5–1) were positive (Figure 1f). 
Despite the small sample size, the data indicated that ASPA 
mutations may be detrimental to cynomolgus monkey embryo 
development. However, we cannot rule out other possibili-
ties leading to the early abortions including, but not limited 
to, rAAV infection and rAAV genome integration. Indeed, we 
previously detected rAAV genome integration in 1 out of 45 
subjects in our mouse study.[2] To characterize potential rAAV 
genome integration, we devised three PCR assays targeting 
different regions of the rAAV.U1a-SpCas9 transgene cassette 
with sensitivities up to 1 in 500 haploid genomes (Figure S5, 
Supporting Information), and two PCR assays detecting poten-
tial integration of the AAV inverted terminal repeats (ITRs) 
at the on-target ASPA locus with sensitivities up to 1 in 30 
haploid genomes (Figure S6, Supporting Information). How-
ever, we did not detect rAAV genome integration in any tissue 
derived from the three gene editing–positive fetuses. In addi-
tion, the variation of gene editing efficiency among individuals 
suggests that not all zygotes were transduced equally despite 
being treated in the same droplet of culture medium, corrobo-
rating the transduction results measured by EGFP fluorescence 
(Figure 1d).
We next pursued to achieve a more robust gene editing 
efficiency using two sgRNAs. We generated another construct 
expressing both sgASPA2 and sgASPA1 (dual-sgASPA) 
(Figure 2a), and confirmed in COS-7 cells that it could induce 
both local indels at the sgRNA targeting sites and large deletions 
Adv. Sci. 2019, 6, 1900440
Figure 2. Dual-guide design achieved efficient genome editing and undetectable off-targeting. a) Schematic showing the construct expressing two 
sgRNAs. b) PCR assay revealing large deletions in the ASPA gene in some embryos infected with rAAV6.SpCas9 and scAAV6.dual-sgASPA. DNA from 
a naïve embryo served as control (ctrl). c) Characterization of ASPA gene editing events in individual embryos by SMRT sequencing. Local indel is 
defined as indel events at either one or both sgRNA targeting sites. Large deletion is defined as deletion between the two sgRNA targeting sites. 
d) ASPA gene editing efficiency of individual embryos as shown in (b) by SMRT sequencing, counting both local indel and large deletion as editing 
events. The horizontal bar indicates the average value.
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in between (Figure S7, Supporting Information). A batch of 
seven zygotes were coinfected with rAAV6.SpCas9 and scAAV6.
dual-sgASPA at 6 × 108 GC total, and individually analyzed for 
dual-sgRNA-induced large deletion by PCR (Figure 2b) and 
ASPA gene editing by SMRT sequencing (Figure 2c). Both 
assays revealed that 5 out of 7 embryos carried large deletions. 
Overall, the average gene editing efficiency was 77% with 5 out 
of 7 embryos exhibiting complete gene editing (Figure 2d), 
which compares favorably with using a single sgRNA at the 
same dose (Figure 1e). Furthermore, we examined the poten-
tial off-targeting (OT) cleavage in these embryos. A total of 
43 candidate OT sites of sgASPA1 (n = 35) and sgASPA2 (n = 8) were 
predicted using the Cas-OFFinder bioinformatics tool (Tables S2 
and S3, Supporting Information), mostly harboring three mis-
matches to the corresponding sgRNAs. Previous work suggested 
that mismatches distal to the protospacer adjacent motif (PAM) 
and fewer mismatches more likely result in OT cleavage.[7] There-
fore, we tested six most susceptible OT sites, i.e., those containing 
either three mismatches within nucleotides 13–20 upstream of 
the PAM (OT1, 2, 3, 5, 6) or two mismatches (OT4) (Figure S8a, 
Supporting Information). T7EI nuclease assay appeared “positive” 
for OT2 and OT5 (Figure S8b, Supporting Information). However, 
the DNA from a naïve embryo showed the same T7EI digestion 
patterns, suggesting irrelevance to Cas9-induced indel mutations. 
Indeed, TOPO cloning and Sanger sequencing of the control 
amplicons of both OT2 and OT5 revealed dimorphic alleles that 
resulted in the T7EI cleavage patterns (Figure S8c, Supporting 
Information). Therefore, no off-targeting cleavage was detected 
at the most susceptible candidate OT sites tested. This result was 
further corroborated by deep sequencing of the candidate off-
target PCR amplicons (Figure S8d,e, Supporting Information). In 
future animal modeling applications, a more comprehensive and 
unbiased off-target analysis can be performed to screen for the 
most appropriate F0 animals as founders.
In summary, we successfully used rAAV to transduce cyn-
omolgus monkey preimplantation embryos, and achieved gene 
editing in embryos and fetuses. Precise gene editing is conceiv-
able by combining with a third rAAV carrying a donor template 
for homology-directed repair (HDR) as demonstrated in mouse 
embryos,[2,8] or by delivering base editors using rAAV.[9,10] 
Although we were not able to obtain any live birth positive for 
gene editing, it may be a gene-specific phenomenon. Alterna-
tively, the infection could be further optimized to reduce the 
rAAV dose for toxicity amelioration. For example, a smaller 
Cas9 variant and sgRNA genes can be packaged within a single 
AAV vector,[11] so that infection can be potentially performed at 
half of the current dose. Recently, another independent group 
reported data corroborating our findings in mice and expanded 
the utility of this technique to rats.[8] Taken together, this rAAV-
mediated approach offers unparalleled ease and efficiency of 
gene delivery to preimplantation embryos, and is potentially 
suitable to a broad range of mammalian species. In addition to 
gene editing and animal modeling, this method can also facili-
tate gene function studies in early-stage mammalian embryos.
Experimental Section
Animals: Healthy female cynomolgus monkeys (Macaca fascicularis) of 
5–10 years old and weighing between 3.62 and 5.90 kg were used in this 
study. All animals were housed at a facility accredited by the Association 
for Assessment and Accreditation of Laboratory Animal Care. All animal 
protocols were approved in advance by the Institutional Animal Care 
and Use Committee of Yunnan Key Laboratory of Primate Biomedical 
Research.
Animal Procedures and Preparation of Zygotes: Superovulation, 
collection of oocytes, fertilization, and embryo culture were performed as 
previously described.[12–14] In brief, healthy female cynomolgus monkeys 
with regular menstrual cycles were selected as oocyte donors for 
superovulation. Animals were intramuscularly injected with recombinant 
human follicle stimulating hormone (rhFSH; Gonal-f, Merck Serono) 
for eight consecutive days and with recombinant human chorionic 
gonadotropin (rhCG; OVIDREL, Merck Serono) on the ninth day. 
Oocytes were collected by laparoscopic follicular aspiration (STORZ) 
32–35 h after rhCG administration and classified as prophase I (PI; intact 
germinal vesicle), metaphase I (MI; no germinal vesicle, no polar body), 
or metaphase II (MII; one polar body). Only MII oocytes were used 
to perform intracytoplasmic sperm injection. Adult male cynomolgus 
monkeys of 7–10 years old with fertility were chosen as sperm donors. 
Semen collection was performed by electroejaculation. The fertilization 
was confirmed by the presence of two pronuclei. Embryos from 1-cell 
stage to blastocyst were cultured in chemically defined, protein-free 
hamster embryo culture medium-9 (HECM-9) containing 10% fetal calf 
serum under 37 °C with 5% CO2 to allow embryo development.
AAV Vectors: For the AAV vectors expressing enhanced green 
fluorescent protein, the self-complementary (sc) recombinant AAV 
genome contained a cytomegalovirus enhancer fused with the chicken 
beta-actin promoter (CMV/CB) driving the EGFP gene. The same genome 
was packaged into various AAV serotype capsids including AAV6, AAV7, 
AAVrh.39, AAVrh.43, and AAV6.2. The single-stranded (ss) AAV6 vector 
expressing Streptococcus pyogenes Cas9 (rAAV6.SpCas9) carried the 
U1a promoter driving SpCas9. The scAAV6 vector expressing a single 
sgRNA (scAAV6.sgASPA) contained the U6 promoter driving sgRNA, 
and the CMV/CB driving EGFP. The scAAV6 vector expressing two 
sgRNAs (scAAV6.Dual-sgASPA) contained two U6-sgRNA cassettes 
in tandem, and the U1a promoter driving EGFP. All AAV vectors were 
produced by triple transfection in HEK293T cells and purified by two 
rounds of CsCl sedimentation. The titers were determined by droplet 
digital PCR (ddPCR, Bio-Rad), and the purity was assessed by protein gel 
electrophoresis and silver staining.
Infection of Zygotes with AAV Vectors: Zygotes obtained by ICSI were 
maintained in HECM-9 medium for 4 h until infection. No more than 
10 zygotes were placed in a droplet of 60 µL of HECM-9 medium 
containing various amounts of AAV vectors as indicated. Zygotes were 
incubated with AAV vectors for various durations as indicated, rinsed, 
and cultured in HECM-9 medium for either seven days for microscopy 
and DNA analysis, or for one day followed by transfer to recipients.
Cell Culture and Transfection: COS-7 cells (ATCC, Cat. No. CRL-1651) 
were maintained in Dulbecco’s Modified Eagle Media (DMEM, Thermo 
Fisher Scientific, Cat. No. 11965084) with 10% fetal bovine serum (FBS, 
Thermo Fisher Scientific, Cat. No. 10438034) under standard cell culture 
condition. COS-7 cells were split into 6-well plates to obtain ≈80% 
density for transfection the next day. Transfection was performed using 
Lipofectamine 2000 (Thermo Fisher Scientific, Cat. No. 11668-019) 
with 0.8 µg of the plasmid expressing SpCas9 and 0.8 µg of a plasmid 
expressing one or two sgRNAs (1.6 µg of total plasmid DNA per well).
DNA Preparation: For COS-7 cells, genomic DNA was isolated three 
days after transfection using the QIAmp DNA Mini Kit (Qiagen, Cat. 
No. 51306). The same kit was used to extract genomic DNA from animal 
tissues. For embryos cultured for seven days ex vivo, individual embryos 
were subjected to whole-genome amplification using the REPLI-g Single 
Cell Kit (Qiagen, Cat. No. 150343).
T7EI Nuclease Assay: A portion of the genomic sequence harboring 
a sgRNA targeting site was amplified using the KOD Hot Start DNA 
Polymerase (EMD Millipore, Cat. No. 71086), and purified using the 
QIAquick PCR purification kit (Qiagen, Cat. No. 28106). Approximately 
350 µg of purified PCR product was denatured and reannealed as 
described previously,[15] and incubated with 10 units of T7EI nuclease 
Adv. Sci. 2019, 6, 1900440
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(NEB, Cat. No. M0302L) under 37 °C for 30 min. The reaction was 
quenched by adding 0.75 µL of 0.5 m EDTA. The entire reaction mixture 
was resolved on a 2% agarose gel containing ethidium bromide and 
imaged.
TOPO Sequencing: Purified PCR product was cloned into the 
pCR-Blunt II-TOPO vector using the Zero Blunt TOPO PCR Cloning 
Kit (Thermo Fisher Scientific, Cat. No. K280002), and transformed 
into DH5α Escherichia coli bacteria. Plasmid of individual colonies was 
isolated using the QIAprep Spin Miniprep Kit (Qiagen, Cat. No. 27106), 
and sequenced by Sanger method.
Detection of rAAV Genome Integration by PCR: The pAAV.SpCas9 
plasmid was linearized by SacII digestion, purified using the QIAquick 
PCR Purification Kit (Qiagen, Cat. No. 28106), and quantified by Qubit 
3.0 Fluorometer (Thermo Fisher Scientific). Linearized plasmid was 
10× serially diluted and used as template in PCR to determine assay 
sensitivity. Each PCR also contained 100 ng of human genomic DNA as 
background. 100 ng of monkey tissue DNA was subjected to the same PCR 
to detect rAAV genome. To specifically assess ITR integration, a portion of 
Cynomolgus ASPA genomic DNA containing the sgASPA target site was 
modified to contain a SbfI site between the 3rd and 4th bps upstream of 
the PAM, synthesized (gBlock, IDT), and cloned into pcDNA3.1 between 
the MluI and XhoI sites to yield pcDNA.CynoASPA-SbfI. The pAAV.SpCas9 
was digested with SbfI, and the fragment containing the rAAV genome 
(containing both ITRs) was cloned into pcDNA.CynoASPA-SbfI to yield 
pcDNA.CynoASPA.ITR-U1a-SpCas9-ITR. This plasmid was digested using 
BglII, and the two fragments were used as templates in upstream and 
downstream ITR integration PCR, respectively. All PCR primers are listed 
in Figure S9c in the Supporting Information.
Single-Molecule Real-Time Sequencing and Bioinformatics Analysis: 
Target amplicons from genomic material for single-molecule real-time 
sequencing was generated by PCR using asymmetrically barcoded primers 
(Figure S9b, Supporting Information). PCR products were pooled at 
equimolar ratios for SMRTbell template preparation and sequenced using 
a PacBio RS II sequencer following standard guidelines and procedures 
by the University of Massachusetts Medical School, Deep Sequencing 
Core. Raw reads were processed by SMRT Analysis software (v2.3.0) 
pipelines to produce reads-of-inserts (ROIs) representing multiplexed 
PCR amplicon sequences in fastq format. All downstream workflows 
were performed using the Galaxy web-based platform for genome data 
analysis,[16–18] unless specified. ROIs were demultiplexed by both 5′ and 
3′ barcodes so that only full and intact reads that encompassed both 
asymmetric barcodes were considered for analysis. Filtered sequences 
were then aligned with BWA-MEM[19] to custom references. For embryos 
treated with a single sgRNA, the reference used was the unedited, wild-
type target amplicon sequence of the cynomolgus monkey ASPA gene. 
Mapped reads exhibiting imperfect alignment (deletions, insertions, 
and mismatches) across the predicted edit site (−3 nt of the PAM) were 
designated as editing events. For embryos treated with two sgRNAs, 
which may result in a 76 bp deletion, reads were aligned to a fasta file 
containing a full-length amplicon sequence and a sequence that lacked 
the 76 nucleotides between the two anticipated cut sites. This method 
improved mapping accuracy. Reads mapping to the full-length sequence 
as imperfect alignments (deletions, insertions, and mismatches) 
across the predicted edit site (−3 nt of the PAM) were designated as 
editing events resulting in local indel events. Reads mapping to the 
reference containing the 76 nt deletion, were considered large deletion 
events. To tabulate the number of editing events in each sample, 
mapped reads where converted to fasta format and were clustered 
with USEARCH v8.1 sequence analysis tools.[20] Specifically, identical 
sequences were tabulated with the -derep_fulllength command, followed 
by sequence clustering using operational taxonomic units (OTU) 
with the -cluster_otus command with the following options: -fulldp, 
-otu_radius_pct 0.1, -minsize 5, -gapopen *I/1.0E, and -gapext *I/0.5E. 
Sequence clusters were manually curated to group and count unique 
indel types. Editing prevalence was scored as a percentage of total reads.
Bioinformatic Prediction of Candidate Off-Targeting Sites: The 
web-based tool Cas-OFFinder (www.rgenome.net/cas-offinder/)[21] 
was used to predict candidate off-targeting sites of sgASPA1 and 
sgASPA2 in the cynomolgus monkey genome. The search parameters 
were set as: PAM type was “SpCas9 from Streptococcus pyogenes: 
5′-NGG-3′”; target genome was “Macaca fascicularis (5.0)—Crab-
eating macaque”; mismatch number was equal or less than 3. Query 
Sequences were “GATTCAGAGAACAGGGCTGG” for sgASPA1, and 
“CTATCTTTGGAGGAACCCAT” for sgASPA2. In total, 35 OT sites were 
predicted for sgASPA1, and 8 OT sites were predicted for sgASPA2.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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